Drug Profile

Carfilzomib - Onyx Pharmaceuticals

Alternative Names: Kyprolis; ONO-7057; PR-171

Latest Information Update: 27 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Proteolix
Developer AbbVie; Amgen; Dana-Farber Cancer Institute; Genentech; GSK; Janssen Biotech; M. D. Anderson Cancer Center; Ohio State University Comprehensive Cancer Center; Ono Pharmaceutical; Onyx Pharmaceuticals; Phoenix Children's Hospital; Roswell Park Cancer Institute; The Innovative Therapies for Children with Cancer; Therapeutic Advances in Childhood Leukemia & Lymphoma; University of Alabama at Birmingham; University of Birmingham; University of California at San Francisco; University of California, Davis; University of Rochester; University of Texas M. D. Anderson Cancer Center
Class Antineoplastics; Epoxy compounds; Oligopeptides; Small molecules
Mechanism of Action Proteasome inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple myeloma; Waldenstrom's macroglobulinaemia; Precursor cell lymphoblastic leukaemia-lymphoma
New Molecular Entity Yes
Available For Licensing Yes - Multiple myeloma

Marketed Multiple myeloma
Phase III Waldenstrom's macroglobulinaemia
Phase II Mantle-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Renal cell carcinoma
Phase I/II Diffuse large B cell lymphoma; Peripheral T-cell lymphoma; Small cell lung cancer; Solid tumours
No development reported Leukaemia; Lymphoid leukaemia; Lymphoma; Non-Hodgkin's lymphoma; Systemic lupus erythematosus

01 Dec 2025 University of Chicago, Bristol-Myers Squibb and Amgen completes a phase II trial for Multiple myeloma (Combination therapy, First-line therapy, Newly diagnosed) in USA (IV) (NCT02969837)
28 Nov 2024 No recent reports of development identified for phase-I development in Multiple-myeloma in USA (IV, Infusion)
01 Oct 2024 Amgen completes the phase II SELECT trial in Multiple myeloma (Combination therapy, Second-line therapy or greater) in USA, Denmark, Estonia, France, Germany, Greece, Italy, Spain (IV) (NCT04191616) (EudraCT2019-001169-34)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com